CSF3 and infection: Given the elevated risk of severe bacterial infections and an associated enhanced malignancy risk in patients requiring high doses of G-CSF (21), JAGN1 patients with documented hyporesponsiveness to G-CSF and severe infection phenotype should be considered early for HSCT.